Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
Vertex Pharmaceuticals(VRTX) stock is priced at $498.10, giving the company a market capitalization of 126.76B. It carries a P/E multiple of 32.58.
During the trading session on 2026-03-11, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $507.92 and a low of $477.77. At a current price of $498.10, the stock is +4.3% higher than the low and still -1.9% under the high.
Trading volume for Vertex Pharmaceuticals(VRTX) stock has reached 3.36M, versus its average volume of 1.38M.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
VRTX News
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive late-stage trial results for kidney disease drug povetacicept in IgA nephropathy. The drug met both pr...
Wolfe Research analyst Andy Chen upgraded Vera Therapeutics (VERA) to Outperform from Peer Perform with an $88 price target. Vertex’s (VRTX) reported interim da...
Vertex Pharmaceuticals VRTX announced positive data from an interim analysis of the ongoing phase III RAINER study, which evaluated its investigational drug pov...
Analyst ratings
76%
of 33 ratingsMore VRTX News
Vertex Pharmaceuticals (VRTX) stock is up 10% on March 10 after the biotechnology company said that its experimental drug for a rare kidney disease succeeded in...
In early trading on Tuesday, shares of Vertex Pharmaceuticals, topped the list of the day's best performing components of the S&P 500 index, trading up 7.8%. Ye...
The stock’s rise comes as the company is reportedly making significant strides in its clinical development. Vertex’s Phase 3 RAINIER Trial Success Vertex anno...
After Vertex (VRTX) reported interim data from its Phase 3 trial of povetacicept in IgA nephropathy patients, BofA said the topline data, which was in-line with...
Oppenheimer raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $600 from $540 and keeps an Outperform rating on the shares. The firm notes the c...
Advertisement Recent Share Performance Snapshot Vertex Pharmaceuticals (VRTX) has attracted attention after a mixed stretch for the stock, with a small 1 day...
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial evalua...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.